Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.
New Jersey A1526 establishes a Psilocybin Behavioral Health Access and Therapy Pilot Program to research the safety and efficacy of psilocybin in treating behavioral health conditions. The Department of Health will oversee the pilot program, which will involve three hospitals selected from different regions of the state. The Psychedelic Therapy and Research Advisory Board, comprising 11 members, will guide the program. The board will research studies, evaluate outcomes, and recommend a comprehensive plan for psilocybin access in New Jersey.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.